Carb-X

Call to Action Side Event: Access and stewardship plans during antibiotic research and development
2018-11-20 07:30 - 08:45 (America/New_York) | Accra, Ghana, Accra, Ghana
This event is an invitation-only side event to the 2nd Call to Action on Antimicrobial Resistance hosted by the Access to Medicine Foundation, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research & Development Partnership (GARDP). In this session, the Access to Medicine Foundation, CARB-X and GARDP will share how they guide, support and partner with pharmaceutical companies to achieve access and stewardship goals. Presentations will be followed by an open discussion related to the role of different sectors in improving access and stewardship strategies during the R&D process.

6th annual meeting of the Boston Area Antibiotic Resistance Network
2018-12-07 08:30 - 19:00 (America/New_York) | Starr Center for Conferences, 185 Cambridge St., Boston, MA, 02114, United States
Speakers include Karen Gallant, Global Program Director of CARB-X.

CARB-X: Combating Antibiotic Resistance Globally
2019-01-15 12:00 - 13:00 (America/New_York)
With Kevin Outterson. A Boston University Alumni Association special webinar event for BU alumni, but all are welcome to join. Register online

ECRAID-Plan Kick-off meeting
2019-01-17 | Brussels, Belgium, Brussels, Belgium
The European Clinical Research Alliance on Infectious Diseases (ECRAID) focuses on two major challenges: emerging infectious diseases (EID) with epidemic or pandemic potential, caused by new or re-emerging pathogens, and antimicrobial resistance (AMR). This meeting aims to bring together the ECRAID-Plan Project Consortium, Working Group, and key stakeholders to constructively discuss ECRAID and its sustainable solutions to protect Europe, and beyond, from AMR and EID threats over the long-term. This is a closed meeting.
Kevin Outterson, Executive Director of CARB-X, will be on the stakeholder advisory panel. Keynote speakers include EU Commissioner for Research, Science and Innovation, Carlos Moedas, and Wellcome Trust Director, Jeremy Farrar.

REVIVE Webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
2019-01-29 11:00 - 12:30 (America/New_York) | WEBINAR, Webinar, Webinar, United States
On the 29th of January 2019, Ian Friedland, Sumathi Nambiar, Mair Powell, and David Shlaes will join us for a live webinar about antibacterial drug enhancer combinations and non-traditional products. Following their short presentations, the speakers will be available on the line to respond to your questions.

Hamied Foundation UK-India Antimicrobial Resistance Meeting 2019
2019-02-04 - 2019-02-05 | The Hallam Conference Centre, 44 Hallam Street, London, United Kingdom
The meeting is being organised as part of a programme of work to strengthen the research links between the UK and India with the specific aim of jointly addressing the challenge of AMR.

Webinar - NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
2019-02-21 17:00 - 18:30 (Europe/Paris) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH, member of the CARB-X Joint Oversight Committee.
In this presentation, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia, industry, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID, irrespective of prior or current NIH funding.
Ann’s presentation will be complemented by a short presentation of Dan Pevear, Founder and Senior Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals, in which he will share VenatoRx’ experience with NIAID support mechanisms.
The presentations will be followed by a Q&A session.

US FDA Regulatory Approval Process for Anti-microbials Workshhop
2019-03-06 | C-CAMP, Chausa, Bengaluru, India
Workshop hosted by the Centre for Cellular And Molecular Platforms (C-CAMP), a member of the CARB-X Accelerator Network.

The 12th Berlin Conference on Life Sciences - Novel Antimicrobials and AMR Diagnostics 2019
2019-03-14 - 2019-03-15 | Radisson Blu Hotel, Karl-Liebknecht-Strasse 3, Berlin, 10178, Germany
Speakers include Kevin Outterson, CARB-X Executive Director.
The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

BSAC Spring Conference 2019
2019-03-21 - 2019-03-22 | International Convention Center, 8 Centenary Square, Birmingham, B1 2EA, United Kingdom
Global views, local problems: Innovative solutions to AMR and infection challenges.
The British Society for Antimicrobial Chemotherapy (BSAC) 2019 Spring Conference offers a state of the art overview of the infection management and antimicrobial resistance landscape. The programme includes keynote lectures, plenary and parallel sessions, debates and an opening series of spotlight presentations – offering insights into the latest in drug discovery and development, socio-economic challenges, new and emerging treatments and diagnostics and debates and challenges policies and usage of antibiotic regimens. Globally focused and locally relevant, the conference brings together key opinion leaders, researchers and clinicians from across Europe and further afield. Alongside the networking and exhibition areas, this event offers outstanding opportunities for education and engagement to all delegates.

Longitude Prize AMR Diagnostics Boston Workshop
2019-03-21 08:30 - 14:00 (America/New_York) | Boston University School of Law, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Kevin Outterson, CARB-X Executive Director.
The Longitude Prize is an international challenge prize competition that will ultimately select one point-of-care diagnostic product to receive a grand payout of 8 million British Pounds ($9.1 million). The winner will have proven that their test can significantly reduce misuse or overuse of antibiotics by creating an affordable, accurate and rapid point-of-care diagnostic test. This test must be practical to use in the North America and Europe as well as low and middle-income countries (LMICs). There are currently 83 teams competing for the Prize from 14 countries with a broad mix of entries from industry and academia. The Prize Rules can be found here.
The purpose of this workshop is to give existing competitors and those interested in competing more information regarding the Longitude Prize competition to help steer projects toward a winning configuration, hear from experts on test needs in the United Kingdom (National Health Service) and lower and middle-income contexts (LMICs), and to provide a chance for test developers to engage with Longitude judges and the Nesta Team.
The Longitude Prize is hosted and managed by the Challenge Prize Centre at Nesta, the Innovation Foundation based in London.
Please RSVP to Ruth Neale at ruth.neale@nesta.org.uk by Friday March 8, 2019 if you plan to attend the workshop.

Inaugural Bacteriophage Therapy Summit
2019-03-25 - 2019-03-27 | Revere Boston Common, 200 Stuart St., Boston, MA, 02116, United States
Speakers include Karen Gallant, CARB-X Global Project Director.
The 1st Bacteriophage Therapy Summit is the only meeting uniting large pharma, biotech companies, research institutions and technology experts to harness bacteriophage science and accelerate the clinical development of effective phage therapy. Join the leaders in phage therapy product development as they discuss the latest data-driven case studies and forge collaborations you need to unlock the full potential of bacteriophage therapeutics.
See the full agenda and speaker list here.
CARB-X subscribers qualify for an exclusive 10% discount with VIP Code 12259CARBX.

The Economist Antimicrobial Resistance Summit - Preventing an Antibiotic Apocalypse
2019-03-26 | BMA House Conference and Events Venue, Tavistock Square, Bloomsbury, London, WC1H 9JP, United Kingdom
Speakers include Kevin Outterson, CARB-X Executive Director.
Join 120+ health policy leaders, academics and other experts across the industry for a frank discussion to catalyse progress in bringing AMR under control, before it is too late. A series of expert panel discussions will dig into the topics that matter the most, using the convening power of The Economist brand to get the right people working together.

GARDP Webinar - Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
2019-03-28 17:00 - 18:30 (Europe/Paris) | Webinar
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.
The webinar will be held from 5:00 pm – 6:30 pm CET / 12:00 pm – 13:30 pm EDT.
The presentations will be followed by a Q&A session.

REPAIR Impact Fund is open for investment proposals...
2019-04-01
…from European life science companies until May 10. Information about how to apply can be found at here.

The REPAIR Impact Fund is now open for investment proposals from European life science companies targeting AMR. Companies are invited to submit a non-confidential proposal, which will be evaluated during the spring. Successful projects will be invited to submit more extensive confidential proposals.

The window for submissions will be open until May 10th. Additional information and the proposal template can be found here.

This investment round is the second to European companies. Companies that took part in the first investment round without obtaining funding are very welcome to take part in this new round.

Annual ECCMID Meeting
2019-04-13 - 2019-04-16 | RAI Amsterdam, Europaplein, Amsterdam, NL 1078 GZ, Netherlands
ECCMID, as the world’s premier Clinical Microbiology & Infectious Diseases event, brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 12,000 colleagues. This year, the Programme Committee has developed a multi-faceted program incorporating keynote lectures and oral sessions, as well as interactive workshops, meet-the-expert sessions, and a wide range of symposia.

19th World Vaccine Congress
2019-04-15 | Renaissance Washington DC Downtown Hotel, 999 9th St NW, Washington, DC, 20001, United States
Speakers include Dr. Barry Eisenstein, Chair of the CARB-X Advisory Board.
For the past 18 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, with: 300 speakers, 1500 attendees and hundreds of networking opportunities. This year’s congress will feature a variety of pre-congress workshops and conferences in:

Cancer Immunotherapy
Immune Profiling
Respiratory Vaccines
Emerging & Re-emerging Diseases
Clinical Trials
Vaccine Partnerships
Bioprocessing & Manufacturing
Vaccines Safety
Logistics
Veterinary Vaccines

Throughout these sessions participants will learn how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market.

ICOHAR, International Conference on One Health Antimicrobial Resistance
2019-04-16 - 2019-04-18 | Jaarbeusplein, Ulrecht, Netherlands
It is generally recognized that control and prevention of antimicrobial resistance (AMR) requires a holistic One Health approach involving specialists from different sectors. In line with this concept, the 2nd ICOHAR aims to bring together representatives from all relevant sectors (e.g. public health, human and veterinary medicine, livestock production, food safety and environmental sciences) to share research and education strategies for understanding and reducing the risks of AMR at the interphase between humans, animals and the environment. The programme does not only focus on zoonotic transfer of AMR but also on the numerous AMR-related challenges shared by clinicians, clinical microbiologists, infectious disease specialists and researchers working in these sectors.
To view the program, please click here.

Annual SHEA (Soc. for Hospital Epidemiology of America) Spring meeting
2019-04-24 - 2019-04-26 | Westin Boston Waterfront, 425 Summer St, Boston, MA, 02210, United States
This conference is designed for physicians, infection preventionists, healthcare epidemiologists, infectious disease specialists, microbiologists, nurses, pharmacists, and other healthcare professionals interested in healthcare epidemiology, infection prevention, Antimicrobial Stewardship, surveillance, research methods, patient safety, environmental issues, and quality improvement.
The SHEA 2019 Program Committee combines the expertise of SHEA members who have served on SHEA meeting planning committees for many years and active leaders from the SHEA Education Committee. It also includes broad subject matter expertise in healthcare epidemiology, antibiotic stewardship, long-term care, research methods, clinical microbiology, patient safety and quality, implementation science, and a wide range of opportunities for networking and communication with peers and experts in the field.
To view the agenda, please click here.

National Academy of Sciences 155th Annual Meeting
2019-04-28 - 2019-05-01 | National Academy of Sciences, 2101 Constitution Ave., N.W., Washington, DC, United States
Advising the Nation. Advancing the Discussion. Connecting New Frontiers.
Society is facing an array of complex policy questions. The National Academies of Sciences, Engineering, and Medicine provides nonpartisan, objective guidance for decision makers on pressing issues. and marshals the energy and intellect of the nation’s critical thinkers to respond to policy challenges with science, engineering, and medicine at their core.
Through a meticulous process of information collection, evidence analysis, and deliberation, NAS studies provide blueprints for progress. By shining a spotlight on subjects and facilitating dialogue across disciplines, their work advances understanding of critical issues.
For information on live webcasts, click here.
For information on the agenda click here.
Visit the NAS website here.

37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID)
2019-05-06 - 2019-05-11 | Ljubljana, Slovenia
The 37​th Annual Meeting of the European Society for Paediatric Infectious Diseases will feature a wide range of sessions and learning opportunities showcasing the latest research and developments in the field hosted by leading international experts. The meeting aims to bring together the most prominent researchers in the field of paediatric infectious diseases, immunology and epidemiology and to fill in the gaps between these disciplines in a relaxed, smart albeit casual atmosphere.

Live Webinar: CARB-X 2019 Funding Rounds
2019-05-16 09:00 - 10:00 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Kevin Outterson, CARB-X Executive Director, and Karen Gallant, CARB-X Global R&D Project Director, present details of CARB-X’s four new funding rounds announced April 30, 2019, and answer questions during this webinar. To attend the live webinar, please register by clicking the link below. A recording of the webinar will be available for viewing shortly after the event. The recording will be available on the CARB-X website in the Apply > What CARB-X funds section.
Please click here to register.

GARDP Mining Chemical Libraries for New Antibacterials
2019-05-21 17:00 - 18:30 (Europe/Helsinki) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) will discuss screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.
Please note, this webinar has been rescheduled from April 4th to May 21st, 2019.
The webinar will be held from 5:00 pm – 6:30 pm CEST / 11:00 pm – 12:30 pm EDT.
The presentation will be followed by a Q&A session.
Register here for this live webinar.

Global AMR R&D Hub “Increasing Investments for AMR R&D” Workshop
2019-05-28 | Domaine de Penthes, Chemin de l'Impératrice 18, Pregny-Chambésy, 1292, Switzerland
Participants include Kevin Outterson, Executive Director of CARB-X.
The Global AMR R&D Hub is pleased to announce a one-day workshop on “Increasing Investments
for AMR R&D”, which will take place on Tuesday May 28 2019 in Geneva, Switzerland. The event
will gather representatives from governments, funders, industry, investors and other stakeholders
interested in the field of antimicrobial resistance.
Antimicrobial resistance (AMR) represents an urgent major global health threat. Currently, there is
an insufficient number of treatments and tools in the AMR research and development (R&D)
pipeline to tackle this issue. Building on ongoing initiatives, increasing investments across the One
Health spectrum is required. In particular, more effort is needed in the animal and plant fields as
well as applicability in low- and middle-income countries (LMIC).
This workshop aims to discuss investments and financing mechanisms for AMR R&D and provide
recommendations for funders and investors on how to address the vital issue of increasing
investments in AMR R&D in a One Health context that also considers applicability in LMIC.
Please click here to learn more.

CARB-X Presentation: 2019 Funding Rounds
2019-05-31 10:00 - 11:45 (America/New_York) | North Carolina Biotechnology Center, 15 T.W. Alexander Drive, Research Triangle Park, NC, 27709-3547, United States
Presentation by Karen Gallant, CARB-X Acting R&D Chief/Deputy Director. Attendees include Richard Alm, CARB-X Alliance Director.
Please join NCBiotech and RTI International as we host CARB-X Global R&D Project Director Karen Gallant for an informational session about CARB-X and the upcoming funding rounds. Karen will provide an overview of the CARB-X initiative and leave plenty of time to get all questions answered. This event is FREE to attend.
For further information, please refer to the CARB-X press release and website.

Agenda
10:00 a.m. – Presentation by Karen Gallant, Global R&D Project Director, CARB-X
10:30 a.m. – Presentation: RTI International as a CARB-X Accelerator
10:45 a.m. – Q&A Session
11:15 a.m. – Networking
11:45 a.m. – Adjourn

Registration
There is some availability for a few companies to have one-on-one meetings with CARB-X. If you are interested, please select that option on the registration page.

2019 BIO International Convention
2019-06-03 - 2019-06-06 | Philadelphia Convention Center, 1101 Arch Street, Philadelphia, PA, 19107, United States
The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. BIO brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 67 countries.
See the schedule here.

Live Webinar: GARDP/REVIVE Mining Chemical Libraries for New Antibacterials - Session 2
2019-06-04 13:30 - 15:00 (Europe/Berlin) | Boston University School of Law, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products.
In this webinar the recording of Carl Balibar’s presentation ‘Mining of chemical libraries for new antibacterials’ (original webinar on 21 May) will be followed by another live Q&A session with Carl.
Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) will discuss screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.
Speakers:
Carl Balibar, Principal Scientist, Merck Research Laboratories
Moderator:
Benjamin Blasco, Discovery Senior Project Manager, GARDP
Register here for this live webinar.

Medical, Biomedical & Biodefense: Support to the Warfighter Symposium
2019-06-05 - 2019-06-06 | The Friday Conference Center, 100 Friday Center Drive, Chapel Hill, NC, 27599, United States
Panelists members include Kevin Outterson, Executive Director of CARB-X, on the “Public-Private Partnerships: Research and Development Consortia and Accelerators” panel.

This panel will discuss the use of public-private partnerships as models for stimulating innovation through sponsored research and development. The panelists will provide overviews of several partnership-enabled consortia and accelerators, including BARDA’s new Division of Research, Innovation, and Ventures and their participation in the partnership, Combating Antibiotic Resistant Bacteria, and, as well as DoD’s Medical CBRN Defense Consortium and Medical Technology Enterprise Consortium. Presenters will discuss their organization’s background and structure, as well as their unique mechanisms for engaging the research community to solve significant public health and biomedical challenges.

The Symposium will focus on two separate tracts. The first, “Medical Support to the Warfighter,” will connect businesses and university researchers with military and other federal agencies that require or purchase medical supplies, equipment, devices, pharmaceuticals, information technology and services, or fund medical-related research and development.
The second tract, “Biomedical and Biodefense Support to the Warfighter,” will focus on establishing dialogue between industry and academia-based technology innovators and military and government officials to address the future biomedical and biodefense needs of the military and our nation.

To learn more, please click here.

Live Webinar: Funding Opportunities for Antimicrobial Drug Development from the Cystic Fibrosis Foundation
2019-06-11 10:00 - 11:00 (America/New_York) | Boston University School of Law, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Interested in new funding opportunities for infection drug development?
The Cystic Fibrosis Foundation (CFF) has teamed up with CARB-X to host a live webinar on June 11, from 10:00am – 11:00am ET, to introduce their new Infection Research Initiative.
During the webinar, Dr. Ann Field, Senior Director of Drug Discovery and Development at the Cystic Fibrosis Foundation, will discuss potential funding opportunities for therapeutic development of anti-infectives in key organisms of interest for CF infections. The presentation will be followed by an interactive Q&A session.
Webinar Summary
Learn about funding opportunities for infection drug development through the Cystic Fibrosis Foundation. This webinar will include:

Overview of the CF Foundation and the recently announced Infection Research Initiative
CF Foundation interest in supporting therapeutic development for anti-infectives in key organisms of interest for CF infections
Therapeutic Development Award Process and collaboration opportunities

To join this webinar, please register here.
If you have questions or comments, please let us know. Feel free to email your questions or comments to Raj Shetty at dshetty@carbx.org before the webinar, or save them for the live Q&A session following the presentation. We look forward to hearing from you!

Live Webinar: GARDP/REVIVE Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research
2019-06-11 17:00 - 18:30 (Europe/Berlin) | Boston University School of Law, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products.
In this webinar, William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy, will introduce experimental design of animal models for antimicrobial research. He will discuss questions such as 1) Where to start and what model to use? 2) Are animal models of bacterial infection reflective of the clinical condition? 3) Are in vivo animal model results predictive of clinical efficacy? The presentation will be followed by a Q&A session moderated by Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec.
Speakers:
William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy
Moderator:
Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec
Register here for this live webinar.
